“…Parwani, Van Spall and Mamas4 comment on potential reasons for underrepresentation of women in HF trials and identify some limitations in the study by Morgan and colleagues 3. As they conclude: “Ultimately, this study confirms what we know about underenrolment of women in HF trials.…”